In Brief: Hoffmann-La Roche/Perkin Elmer
This article was originally published in The Gray Sheet
Hoffmann-La Roche/Perkin Elmer: Enter licensing agreement under which Perkin Elmer's Applied Biosystems Division will develop commercial diagnostic systems that combine Roche's PCR technology with Perkin Elmer's electrophoretic DNA analysis systems. The agreement provides "non-exclusive, limited rights for manufacturing and worldwide distribution of products incorporating PCR for use in fluorescent electrophoresis systems for human in vitro diagnostics," Perkin Elmer says, noting that the agreement allows the technologies to be "used in early diagnosis and potentially more effective treatment for major illnesses" such as cystic fibrosis, colon cancer and breast cancer...
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.